title: Entecavir plus adefovir versus adefovir plus lamivudine in  hepatitis B virus e antigen-positive, lamivudine-resistant  chronic hepatitis B.
authors.forename: Jeong
authors.initials: J
authors.lastname: Heo
authors.forename: Sang Hoon
authors.initials: SH
authors.lastname: Ahn
authors.forename: Young-Oh
authors.initials: YO
authors.lastname: Kweon
authors.forename: Byung-Ho
authors.initials: BH
authors.lastname: Kim
authors.forename: Henry L Y
authors.initials: HL
authors.lastname: Chan
authors.forename: Andzei
authors.initials: A
authors.lastname: Horban
authors.forename: Suchat
authors.initials: S
authors.lastname: Wongcharatrawee
authors.forename: Cyril
authors.initials: C
authors.lastname: Llamoso
authors.forename: Kwan Sik
authors.initials: KS
authors.lastname: Lee
mesh_terms: D000225:Adenine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D000293:Adolescent; D000328:Adult; D000368:Aged; D000998:Antiviral Agents / Q000008:administration & dosage*; D024882:Drug Resistance, Viral; D004359:Drug Therapy, Combination; D005260:Female; D006513:Hepatitis B e Antigens / Q000276:immunology* / Q000378:metabolism; D019694:Hepatitis B, Chronic / Q000188:drug therapy* / Q000276:immunology* / Q000821:virology; D006801:Humans; D019259:Lamivudine / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D063065:Organophosphonates / Q000008:administration & dosage*; D013997:Time Factors; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000998:Antiviral Agents; D006513:Hepatitis B e Antigens; D063065:Organophosphonates; D019259:Lamivudine; C053001:adefovir; D000225:Adenine